CoChat

Murine models of Alzheimer's disease and their use in developing immunotherapies

Open access
Wisniewski, Thomas, Sigurdsson, Einar M. · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Cited by 81

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is one of the categories of neurodegenerative diseases characterized by a conformational change of a normal protein into a pathological conformer with a high β-sheet content that renders it resistant to degradation and neurotoxic. In AD, the normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The oligomeric forms of Aβ are thought to be the most toxic, while fibrillar Aβ becomes deposited as amyloid plaques and congophilic angiopathy, which both serve as neuropathological markers of the disease. An additional important feature of AD is the accumulation of abnormally phosphorylated tau as soluble toxic oligomers and as neurofibrillary tangles. Many therapeutic interventions are under investigation to prevent and treat AD. The testing of these diverse approaches to ameliorate AD pathology has been made possible by the existence of numerous transgenic mouse models which each mirror specific aspects of AD pathology. None of the current murine models is a perfect match of the human disease. Perhaps the most exciting of the therapeutic approaches being developed is immunomodulation targeting the aggregating proteins, Aβ and tau. This type of AD therapy is currently being assessed in many transgenic mouse models, and promising findings have led to clinical trials. However, there is a discrepancy between results in murine models and ongoing clinical trials, which highlight the limitations of these models and also of our understanding of the underlying etiology and pathogenesis of AD. Because of these uncertainties, Tg models for AD are continuously being refined with the aim to better understand the disease and to enhance the predictive validity of potential treatments such as immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2010.05.004

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 134

  1. Rafii, 2009, Recent developments in Alzheimer's disease therapeutics, BMC Med., 7, 7, 10.1186/1741-7015-7-7 · DOI · Paper page
  2. Biran, 2009, Pharmacotherapeutic targets in Alzheimer's disease, J. Cell. Mol. Med., 13, 61, 10.1111/j.1582-4934.2008.00595.x · DOI · Paper page
  3. Wisniewski, 2010, Vaccination as a therapeutic approach for Alzheimer's disease, Mt. Sinai J. Med., 77, 17, 10.1002/msj.20156 · DOI · Paper page
  4. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  5. Hardy, 2006, A hundred years of Alzheimer's disease research, Neuron, 52, 3, 10.1016/j.neuron.2006.09.016 · DOI · Paper page
  6. Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
  7. King, 2006, tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid, J. Cell Biol., 175, 541, 10.1083/jcb.200605187 · DOI · Paper page
  8. Sigurdsson, 1996, Local and distant histopathological effects of unilateral amyloid-beta 25–35 injections into the amygdala of young F344 rats, Neurobiol. Aging, 17, 893, 10.1016/S0197-4580(96)00169-8 · DOI
  9. Sigurdsson, 1997, Bilateral injections of amyloid-beta 25–35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects, Neurobiol. Aging, 18, 591, 10.1016/S0197-4580(97)00154-1 · DOI
  10. Sigurdsson, 2001, Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice, Am. J. Pathol., 159, 439, 10.1016/S0002-9440(10)61715-4 · DOI · Paper page
  11. Morgan, 2000, Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408, 982, 10.1038/35050116 · DOI · Paper page
  12. Sigurdsson, 2004, An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives, J. Neurosci., 24, 6277, 10.1523/JNEUROSCI.1344-04.2004 · DOI · Paper page
  13. Asuni, 2006, Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice, Eur. J. Neurosci., 24, 2530, 10.1111/j.1460-9568.2006.05149.x · DOI · Paper page
  14. Blurton-Jones, 2006, Pathways by which Abeta facilitates tau pathology, Curr. Alzheimer Res., 3, 437, 10.2174/156720506779025242 · DOI · Paper page
  15. McKee, 2008, Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice, Brain Res., 1207, 225, 10.1016/j.brainres.2008.01.095 · DOI · Paper page
  16. Shioi, 2007, FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta, J. Neurochem., 101, 674, 10.1111/j.1471-4159.2006.04391.x · DOI · Paper page
  17. Masliah, 2001, Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, J. Neuropathol. Exp. Neurol., 60, 357, 10.1093/jnen/60.4.357 · DOI · Paper page
  18. Hsiao, 1996, Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice., Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
  19. Fryer, 2003, Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice, J. Neurosci., 23, 7889, 10.1523/JNEUROSCI.23-21-07889.2003 · DOI · Paper page
  20. Frautschy, 1998, Microglial response to amyloid plaques in APPsw transgenic mice, Am. J. Pathol., 152, 307
  21. Tan, 1999, Microglial activation resulting from CD40–CD40L interaction after beta-amyloid stimulation, Science, 286, 2352, 10.1126/science.286.5448.2352 · DOI · Paper page
  22. Pappolla, 1998, Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo, Am. J. Pathol., 152, 871
  23. Smith, 1998, Amyloid beta deposition in Alzheimer transgenic mice is associated with oxidative stress, J. Neurochem., 70, 2212, 10.1046/j.1471-4159.1998.70052212.x · DOI · Paper page
  24. Arendash, 2001, Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes, Brain Res., 891, 42, 10.1016/S0006-8993(00)03186-3 · DOI · Paper page
  25. Tagliavini, 1991, Amyloid protein of Gerstmann–Straussler–Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N- terminal glycine at codon 58, EMBO J., 10, 513, 10.1002/j.1460-2075.1991.tb07977.x · DOI · Paper page
  26. Rockenstein, 2001, Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42), J. Neurosci. Res., 66, 573, 10.1002/jnr.1247 · DOI · Paper page
  27. Moechars, 1999, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J. Biol. Chem., 274, 6483, 10.1074/jbc.274.10.6483 · DOI · Paper page
  28. Kumar-Singh, 2000, Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation, Neurobiol. Dis., 7, 9, 10.1006/nbdi.1999.0272 · DOI · Paper page
  29. Brouwers, 2008, Molecular genetics of Alzheimer's disease: an update, Ann. Med., 40, 562, 10.1080/07853890802186905 · DOI · Paper page
  30. Wolfe, 2009, gamma-Secretase in biology and medicine, Semin. Cell Dev. Biol., 20, 219, 10.1016/j.semcdb.2008.12.011 · DOI
  31. Duff, 1996, Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1, Nature, 383, 710, 10.1038/383710a0 · DOI · Paper page
  32. Holcomb, 1998, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat. Med., 4, 97, 10.1038/nm0198-097 · DOI · Paper page
  33. Wilhelmus, 2007, Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease, Mol. Neurobiol., 35, 203, 10.1007/s12035-007-0029-7 · DOI · Paper page
  34. Wisniewski, 2008, Preventing Aβ fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors, BMC Neurosci., 9, 1, 10.1186/1471-2202-9-S2-S5 · DOI
  35. Prelli, 1988, Differences between vascular and plaque core amyloid in Alzheimer's disease, J. Neurochem., 51, 648, 10.1111/j.1471-4159.1988.tb01087.x · DOI · Paper page
  36. Mahley, 2009, Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches, Ann. Neurol., 65, 623, 10.1002/ana.21736 · DOI
  37. Wisniewski, 1993, Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid, Biochem. Biophys. Res. Commun., 192, 359, 10.1006/bbrc.1993.1423 · DOI · Paper page
  38. Wisniewski, 1994, Alzheimer's disease and soluble Aβ, Neurobiol. Aging, 15, 143, 10.1016/0197-4580(94)90105-8 · DOI
  39. Bales, 1999, Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease, Proc. Natl Acad. Sci. U. S. A., 96, 15233, 10.1073/pnas.96.26.15233 · DOI · Paper page
  40. Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
  41. Calon, 2004, Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model, Neuron, 43, 633, 10.1016/j.neuron.2004.08.013 · DOI · Paper page
  42. Dziewczapolski, 2009, Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease, J. Neurosci., 29, 8805, 10.1523/JNEUROSCI.6159-08.2009 · DOI · Paper page
  43. Colton, 2006, NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 103, 12867, 10.1073/pnas.0601075103 · DOI · Paper page
  44. Wilcock, 2009, Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease, J. Neurosci., 29, 7957, 10.1523/JNEUROSCI.1339-09.2009 · DOI · Paper page
  45. Zhang-Nunes, 2006, The cerebral beta-amyloid angiopathies: hereditary and sporadic, Brain Pathol., 16, 30, 10.1111/j.1750-3639.2006.tb00559.x · DOI · Paper page
  46. Domnitz, 2005, Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease, J. Neuropathol. Exp. Neurol., 64, 588, 10.1097/01.jnen.0000171644.00180.fc · DOI · Paper page
  47. Davis, 2006, Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice, Neurobiol. Aging, 27, 946, 10.1016/j.neurobiolaging.2005.05.031 · DOI
  48. Xu, 2007, Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice, Neuroscience, 146, 98, 10.1016/j.neuroscience.2007.01.043 · DOI
  49. Levy, 1990, Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type, Science, 248, 1124, 10.1126/science.2111584 · DOI · Paper page
  50. Kumar-Singh, 2009, Hereditary and sporadic forms of Abeta-cerebrovascular amyloidosis and relevant transgenic mouse models, Int. J Mol. Sci., 10, 1872, 10.3390/ijms10041872 · DOI · Paper page
  51. Attems, 2004, Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology—a pilot study, Acta Neuropathol. (Berl), 107, 83, 10.1007/s00401-003-0796-9 · DOI · Paper page
  52. Wilcock, 2009, Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease, Neuroscience, 159, 1055, 10.1016/j.neuroscience.2009.01.023 · DOI · Paper page
  53. Zilka, 2009, Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies, Acta Neuropathol., 118, 71, 10.1007/s00401-009-0499-y · DOI
  54. Gotz, 2000, In vivo analysis of wild-type and FTDP-17 tau transgenic mice, Ann. NY Acad. Sci., 920, 126, 10.1111/j.1749-6632.2000.tb06914.x · DOI · Paper page
  55. Ishihara, 2001, Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice, Am. J. Pathol., 158, 555, 10.1016/S0002-9440(10)63997-1 · DOI · Paper page
  56. Tanemura, 2001, Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau, Neurobiol. Dis., 8, 1036, 10.1006/nbdi.2001.0439 · DOI · Paper page
  57. Egashira, 2005, Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice, Brain Res., 1059, 7, 10.1016/j.brainres.2005.08.004 · DOI
  58. Lee, 2005, Transgenic animal models of tauopathies, Biochim. Biophys. Acta, 1739, 251, 10.1016/j.bbadis.2004.06.014 · DOI · Paper page
  59. Murakami, 2006, Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation, Am. J Pathol, 169, 1365, 10.2353/ajpath.2006.051250 · DOI
  60. Rosenmann, 2008, A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics, Exp. Neurol., 212, 71, 10.1016/j.expneurol.2008.03.007 · DOI
  61. Schindowski, 2006, Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits, Am. J. Pathol., 169, 599, 10.2353/ajpath.2006.060002 · DOI · Paper page
  62. Taniguchi, 2005, Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation, FEBS Lett., 579, 5704, 10.1016/j.febslet.2005.09.047 · DOI · Paper page
  63. Mastrangelo, 2008, Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice, BMC Neurosci., 9, 81, 10.1186/1471-2202-9-81 · DOI · Paper page
  64. Boutajangout, 2008, Presenilin 1 mutation promotes tau phosphorylation and aggregation in a novel Alzheimer's disease mouse model, Alz.Dementia, 4, T185, 10.1016/j.jalz.2008.05.504 · doi:10.1016/j.jalz.2008.05.504
  65. Boutajangout, 2009, Influence of presenilin mutation on tau pathology in novel Alzheimer's disease mouse model, Alz Dementia, 5, P445, 10.1016/j.jalz.2009.04.919 · doi:10.1016/j.jalz.2009.04.919
  66. Solomon, 1997, Disaggregation of Alzheimer β-amyloid by site-directed mAb, Proc. Natl Acad. Sci. U. S. A., 94, 4109, 10.1073/pnas.94.8.4109 · DOI · Paper page
  67. Solomon, 2007, Antibody-mediated immunotherapy for Alzheimer's disease, Curr. Opin. Investig. Drugs, 8, 519
  68. Frenkel, 2003, Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization, Vaccine, 21, 1060, 10.1016/S0264-410X(02)00609-6 · DOI
  69. Lavie, 2004, EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials, J. Mol. Neurosci., 24, 105, 10.1385/JMN:24:1:105 · DOI
  70. Schiltz, 2004, Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease, J. Mol. Med., 82, 706, 10.1007/s00109-004-0570-z · DOI
  71. Lemere, 2001, Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease, DNA Cell Biol., 20, 705, 10.1089/10445490152717569 · DOI · Paper page
  72. Sigurdsson, 2001, Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice, Am. J. Pathol., 159, 439, 10.1016/S0002-9440(10)61715-4 · DOI · Paper page
  73. Sigurdsson, 2002, Immunization for Alzheimer's disease, Drug Dev. Res., 56, 135, 10.1002/ddr.10068 · DOI
  74. Wisniewski, 2005, Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease, Brain Pathol., 15, 72, 10.1111/j.1750-3639.2005.tb00102.x · DOI · Paper page
  75. Pride, 2008, Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis, Neurodegener. Dis., 5, 194, 10.1159/000113700 · DOI · Paper page
  76. Wisniewski, 2005, Practice point commentary on, “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial”, Nat. Clin. Pract. Neurol., 1, 84, 10.1038/ncpneuro0019 · DOI
  77. Boche, 2008, The role of the immune system in clearance of Aβ from the brain, Brain Pathol., 18, 267, 10.1111/j.1750-3639.2008.00134.x · DOI · Paper page
  78. Bombois, 2007, Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia, Arch. Neurol., 64, 583, 10.1001/archneur.64.4.583 · DOI · Paper page
  79. Ferrer, 2004, Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease, Brain Pathol., 14, 11, 10.1111/j.1750-3639.2004.tb00493.x · DOI · Paper page
  80. Masliah, 2005, Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease, Neurol., 64, 129, 10.1212/01.WNL.0000148590.39911.DF · DOI · Paper page
  81. Boche, 2008, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, Brain, 131, 3299, 10.1093/brain/awn261 · DOI · Paper page
  82. Sadowski, 2007, Disease modifying approaches for Alzheimer's pathology, Curr. Pharm. Des., 13, 1943, 10.2174/138161207781039788 · DOI · Paper page
  83. Hock, 2003, Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease, Neuron, 38, 547, 10.1016/S0896-6273(03)00294-0 · DOI · Paper page
  84. Hock, 2002, Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease, Nat. Med., 8, 1270, 10.1038/nm783 · DOI · Paper page
  85. Cribbs, 2003, Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid, Int. Immunol., 15, 505, 10.1093/intimm/dxg049 · DOI · Paper page
  86. Maier, 2006, Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response, J. Neurosci., 26, 4717, 10.1523/JNEUROSCI.0381-06.2006 · DOI · Paper page
  87. Agadjanyan, 2005, Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide, J. Immunol., 174, 1580, 10.4049/jimmunol.174.3.1580 · DOI · Paper page
  88. Zamora, 2006, Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice, J. Immunol., 177, 2662, 10.4049/jimmunol.177.4.2662 · DOI
  89. Chackerian, 2006, Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses, Vaccine, 24, 6321, 10.1016/j.vaccine.2006.05.059 · DOI
  90. Jennings, 2008, The coming of age of virus-like particle vaccines, Biol. Chem., 389, 521, 10.1515/BC.2008.064 · DOI · Paper page
  91. Movsesyan, 2008, Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine—a novel immunotherapeutic strategy, PLoS. ONE., 3, e2124, 10.1371/journal.pone.0002124 · DOI · Paper page
  92. Head, 2008, A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta, J Neurosci., 28, 3555, 10.1523/JNEUROSCI.0208-08.2008 · DOI · Paper page
  93. Weiner, 2000, Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease, Ann. Neurol., 48, 567, 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W · DOI · Paper page
  94. Lemere, 2002, Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants, Neurobiol Aging, 23, 991, 10.1016/S0197-4580(02)00127-6 · DOI
  95. Hara, 2004, Development of a safe oral Ab vaccine using recombinant adeno-associated virus vector for Alzheimer's disease, J. Alz. Dis., 6, 483, 10.3233/JAD-2004-6504 · DOI · Paper page
  96. Seabrook, 2006, Dendrimeric Abeta1–15 is an effective immunogen in wildtype and APP-tg mice, Neurobiol Aging, 1
  97. Nikolic, 2007, Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage, Proc. Natl. Acad. Sci. U. S. A, 104, 2507, 10.1073/pnas.0609377104 · DOI · Paper page
  98. Boutajangout, 2009, Lack of cognitive impairment and reduced Aβ burden in Tg2576 mice following acute prophylactic oral immunization with an Aβ derivative, J. Alz. Dis., 18, 961, 10.3233/JAD-2009-1204 · DOI
  99. McLaurin, 2002, Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis, Nat. Med., 8, 1263, 10.1038/nm790 · DOI · Paper page
  100. Levites, 2006, Anti-Aβ42 and anti-Aβ40 specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model, J. Clin. Invest, 116, 193, 10.1172/JCI25410 · DOI · Paper page
  101. Wilcock, 2004, Passive immunization against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J. Neuroinflammation, 1, 24, 10.1186/1742-2094-1-24 · DOI
  102. Wilcock, 2007, Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid, Neuroscience, 144, 950, 10.1016/j.neuroscience.2006.10.020 · DOI
  103. Petrushina, 2008, Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice, J Neuroinflammation., 5, 42, 10.1186/1742-2094-5-42 · DOI
  104. Kramer, 2002, Executive dysfunction in subcortical ischaemic vascular disease, J Neurol Neurosurg. Psychiatry, 72, 217, 10.1136/jnnp.72.2.217 · DOI · Paper page
  105. Sigurdsson, 2008, Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies, J Alzheimers. Dis., 15, 157, 10.3233/JAD-2008-15202 · DOI · Paper page
  106. Noble, 2009, Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding, Prion., 3, 10.4161/pri.3.2.8820 · DOI · Paper page
  107. Kayed, 2009, Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders, Curr. Opin. Immunol., 21, 359, 10.1016/j.coi.2009.05.001 · DOI
  108. Sigurdsson, 2009, Tau-focused immunotherapy for Alzheimer's disease and related tauopathies, Curr. Alzheimer Res., 6, 446, 10.2174/156720509789207930 · DOI · Paper page
  109. Goedert, 1989, Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease, Neuron, 3, 519, 10.1016/0896-6273(89)90210-9 · DOI · Paper page
  110. Utton, 2005, Molecular motors implicated in the axonal transport of tau and alpha-synuclein, J. Cell. Sci., 118, 4645, 10.1242/jcs.02558 · DOI · Paper page
  111. Magnani, 2007, Interaction of tau protein with the dynactin complex, EMBO J., 26, 4546, 10.1038/sj.emboj.7601878 · DOI · Paper page
  112. Morishima-Kawashima, 1995, Hyperphosphorylation of tau in PHF, Neurobiol. Aging, 16, 365, 10.1016/0197-4580(95)00027-C · DOI · Paper page
  113. Brion, 1986, Alzheimer's disease and tau proteins, Lancet, 2, 1098, 10.1016/S0140-6736(86)90495-2 · DOI
  114. Brion, 2006, Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease, J. Alzheimers Dis., 9, 177, 10.3233/JAD-2006-9S321 · DOI
  115. Wang, 2008, Microtubule-associated protein tau in development, degeneration and protection of neurons, Prog. Neurobiol., 85, 148, 10.1016/j.pneurobio.2008.03.002 · DOI · Paper page
  116. Buee, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Brain Res. Rev., 33, 95, 10.1016/S0165-0173(00)00019-9 · DOI · Paper page
  117. Baumann, 1993, Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5, FEBS Lett., 336, 417, 10.1016/0014-5793(93)80849-P · DOI · Paper page
  118. Hamdane, 2003, Mitotic-like tau phosphorylation by p25–Cdk5 kinase complex, J. Biol. Chem., 278, 34026, 10.1074/jbc.M302872200 · DOI · Paper page
  119. Ren, 2009, Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates, Nat. Cell Biol., 11, 219, 10.1038/ncb1830 · DOI · Paper page
  120. Aguzzi, 2009, Cell biology: beyond the prion principle, Nature, 459, 924, 10.1038/459924a · DOI · Paper page
  121. Wisniewski, 1995, Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis, Am. J. Pathol., 147, 238
  122. Jucker, 2008, Cerebral and peripheral amyloid phagocytes—an old liaison with a new twist, Neuron, 59, 8, 10.1016/j.neuron.2008.06.014 · DOI · Paper page
  123. Butovsky, 2007, Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model, Eur. J. Neurosci., 26, 413, 10.1111/j.1460-9568.2007.05652.x · DOI · Paper page
  124. Obregon, 2008, CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation, Neurobiol. Dis., 29, 336, 10.1016/j.nbd.2007.09.009 · DOI
  125. Lee, 2006, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, J. Biol. Chem., 281, 4292, 10.1074/jbc.M511018200 · DOI · Paper page
  126. Moretto, 2007, Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide, J. Biol. Chem., 282, 11436, 10.1074/jbc.M609690200 · DOI · Paper page
  127. Mamikonyan, 2007, Anti-A beta 1–11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers, J. Biol. Chem., 282, 22376, 10.1074/jbc.M700088200 · DOI · Paper page
  128. Maji, 2009, Functional amyloids as natural storage of peptide hormones in pituitary secretory granules, Science, 325, 328, 10.1126/science.1173155 · DOI · Paper page
  129. Kayed, 2003, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science, 300, 486, 10.1126/science.1079469 · DOI · Paper page
  130. Wisniewski, 2009, Immunotherapy targeting abnormal protein conformation, Alz. Dementia, 5, P113, 10.1016/j.jalz.2009.05.354 · DOI
  131. Sigurdsson, 2008, Tau immunotherapy prevents cognitive decline and clears pathological tau in a mouse model, Alz Dementia, 4, T191, 10.1016/j.jalz.2008.05.530 · doi:10.1016/j.jalz.2008.05.530
  132. Wisniewski, 2007, Therapeutic approaches for prion and Alzheimer's diseases, FEBS J., 274, 3784, 10.1111/j.1742-4658.2007.05919.x · DOI
  133. Goni, 2008, High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice, Neurosci., 153, 679, 10.1016/j.neuroscience.2008.02.051 · DOI
  134. Lee, 2005, Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis, FEBS Lett., 579, 2564, 10.1016/j.febslet.2005.03.070 · DOI · Paper page

Cited by

See all 81

Metadata

Authors
Wisniewski, T., & Sigurdsson, E. M.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2010-10
Volume
1802
Issue
10
Pages
847-859
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2041492570
Cited by
81
References
102
FWCI
6.66
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • NIH grants (AG20245, AG15408, AG020197, AG032611)
  • Alzheimer's Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.